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CI

:   confidence interval

DMD

:   Duchenne muscular dystrophy

FEV1

:   forced expiratory volume in 1 sec

FVC

:   forced vital capacity

GC

:   glucocorticoid steroids

IFR

:   inspiratory flow reserve

PEF

:   peak expiratory flow

MEP

:   maximum static expiratory pressure

MIP

:   maximum static inspiratory pressure

MMRM

:   mixed model for repeated measurements

SD

:   standard deviation

V\'I,max(FVC) \[L/sec\]

:   largest inspiratory flow during an inspiratory FVC maneuver

V\'I,max(t) \[L/sec\]

:   largest inspiratory flow during tidal breathing

V\'I,max(t)/V\'I,max(FVC)

:   inspiratory flow ratio

1 − (V\'I,max(t)/V\'I,max(FVC)) \[%\]

:   inspiratory flow reserve (IFR in %)

V\'I,max(FVC) − V\'I,max(t) \[L/sec\]

:   inspiratory flow reserve (IFR in L/sec)

INTRODUCTION {#ppul23547-sec-0002}
============

Duchenne muscular dystrophy (DMD), the most common and severe neuromuscular disorder of childhood, is an inexorably progressive and ultimately fatal X‐linked disease, characterized by muscle degeneration and atrophy.[1](#ppul23547-bib-0001){ref-type="ref"} DMD patients generally lose ambulation before the age of 12 and develop respiratory or cardiac complications in their late teenage years. Routine use of glucocorticoid steroids (GCs) and the introduction of mechanical insufflation--exsufflation devices to improve airway clearance and non‐invasive ventilation to prevent hypoventilation have become standard of care which together have increased survival in DMD to late in the second and frequently well into the third decade.[2](#ppul23547-bib-0002){ref-type="ref"}, [3](#ppul23547-bib-0003){ref-type="ref"}, [4](#ppul23547-bib-0004){ref-type="ref"}, [5](#ppul23547-bib-0005){ref-type="ref"} Indeed, progressive respiratory muscle weakness leads to restrictive respiratory disease, hypoventilation, ineffective cough, recurrent pulmonary infections, atelectasis, and respiratory failure.[6](#ppul23547-bib-0006){ref-type="ref"}, [7](#ppul23547-bib-0007){ref-type="ref"}, [8](#ppul23547-bib-0008){ref-type="ref"} Accordingly, serial measurement of lung function is an important part of the standard of care of patients with DMD.[9](#ppul23547-bib-0009){ref-type="ref"}

Respiratory function and respiratory muscle strength in patients with DMD can be assessed by measuring lung volumes[10](#ppul23547-bib-0010){ref-type="ref"} (e.g., forced vital capacity \[FVC\] and forced expiratory volume in one second \[FEV­­1\]) and flows (peak expiratory flow \[PEF\]) as well as inspiratory and expiratory static airway pressures (e.g., maximal inspiratory pressure \[MIP\] and maximal expiratory pressure \[MEP\]). Since a FVC maneuver requires both maximal inspiration and exhalation, and PEF requires maximal expiratory muscle function, loss of this muscle function will produce a decline in both FVC and PEF.[11](#ppul23547-bib-0011){ref-type="ref"}, [12](#ppul23547-bib-0012){ref-type="ref"}, [13](#ppul23547-bib-0013){ref-type="ref"}, [14](#ppul23547-bib-0014){ref-type="ref"}, [15](#ppul23547-bib-0015){ref-type="ref"} Yet, these maneuvers require maximal effort and cooperation, and can be challenging to perform in young patients and patients with cognitive disability.

In DMD patients, diaphragm and inspiratory muscle function are progressively impaired. Therefore, assessing dynamic inspiratory muscle function may also provide additional information on the status and progression of pulmonary involvement in patients with DMD.[16](#ppul23547-bib-0016){ref-type="ref"} Indeed, the largest flow generated during an inspiratory FVC maneuver (maximum inspiratory flow; V\'I,max(FVC)) is abnormally reduced and the ratio between the largest inspiratory flow during tidal breathing (tidal inspiratory flow; V\'I,max(t)) and the V\'I,max(FVC) is increased and the resulting inspiratory flow reserve (IFR)[16](#ppul23547-bib-0016){ref-type="ref"} consequently decreased.

In a recent Phase 3 randomized, placebo‐controlled clinical trial (DELOS; [ClinicalTrials.gov](http://ClinicalTrials.gov) number: NCT01027884) in patients with DMD not using concomitant GCs, idebenone, a short‐chain benzoquinone, has been shown to reduce the loss of respiratory function as assessed by PEF, FVC, and FEV1 over the 52‐week study period.[17](#ppul23547-bib-0017){ref-type="ref"} The aims of the present analysis were to characterize dynamic inspiratory muscle function in the largest cohort of DMD patients analyzed thus far for this parameter, and to assess the efficacy of idebenone compared to placebo on this inspiratory function outcome in the DELOS population.

PATIENTS AND METHODS {#ppul23547-sec-0003}
====================

The study population consisted of 64 patients aged 10--18 years (mean age, 14.3 years) with a documented diagnosis of DMD. Subjects were enrolled in DELOS, a multi‐center, phase 3 clinical trial comparing the efficacy of 900 mg/day idebenone (Raxone® provided by Santhera Pharmaceuticals, Liestal, Switzerland) compared to placebo.[17](#ppul23547-bib-0017){ref-type="ref"} Patients were eligible if they had a PEF percent predicted (PEF%p) \<80% at baseline and had stopped taking GC at least 12 months prior to enrollment. In addition, patients were not allowed to take GC during the 52‐week study period. Standard spirometry was performed at hospital visits at baseline and at weeks 13, 26, 39, and 52 using a Pneumotrac Spirometer 6800 (Vitalograph, Buckingham, UK) with the aid of a qualified, trained, and certified operator and in accordance with the American Thoracic Society/European Respiratory Society guidelines.[18](#ppul23547-bib-0018){ref-type="ref"} For PEF, FVC, and FEV~1~, the largest available test result from a minimum of three and up to five consecutive maneuvers was used. Since lung volume and associated pulmonary function is influenced by height, race, and age, these measures are presented relative to normative data as percent of predicted, which allows for longitudinal comparison.[17](#ppul23547-bib-0017){ref-type="ref"}, [18](#ppul23547-bib-0018){ref-type="ref"}, [19](#ppul23547-bib-0019){ref-type="ref"}, [20](#ppul23547-bib-0020){ref-type="ref"} Similarly, for MIP and MEP, the highest value from a minimum of three and up to five consecutive maneuvers was used and normalized using established equations.[21](#ppul23547-bib-0021){ref-type="ref"} Patient height was derived from ulnar length measures.[22](#ppul23547-bib-0022){ref-type="ref"}, [23](#ppul23547-bib-0023){ref-type="ref"}

In order to evaluate inspiratory function, patients were asked to breathe normally and perform several tidal breaths into the spirometer. At the end of the inspiratory tidal breathing, the patient was asked to perform a maximal exhalation followed by a maximal inspiratory maneuver to total lung capacity (Fig. [1](#ppul23547-fig-0001){ref-type="fig"}). Patients performed between three and five consecutive inspiratory function maneuvers at each study visit following the PEF and FVC function tests. Sufficient time was allowed for patients to rest between pulmonary function tests as well as between individual maneuvers to minimize fatigue. All available data obtained from inspiratory function tests were recorded and stored without assessment of acceptability, as at this time no acceptance criteria for this maneuver are available. From any individual inspiratory function maneuver, the maximum inspiratory flow during tidal breathing (V\'I,max(t)) and the maximum inspiratory flow during an inspiratory FVC maneuver (V\'I,max(FVC)) was recorded as described by De Bruin et al.[16](#ppul23547-bib-0016){ref-type="ref"} (Fig. [1](#ppul23547-fig-0001){ref-type="fig"}). To limit the influence of both spuriously low and high tidal flow values without requiring a manual assessment of the quality of the tidal breathing, the lowest of the available V\'I,max(t) recorded during a set of consecutive tests was used to calculate the inspiratory flow ratio as the ratio between the V\'I,max(t) determined as described above and the highest V\'I,max(FVC) available from the set of consecutive maneuvers. In addition, the inspiratory flow reserve (IFR), a pre‐specified tertiary endpoint of the DELOS trial, was calculated as 1 -- (V\'I,max(t)/V\'I,max(FVC)) and expressed as percentage. According to data from De Bruin et al.,[16](#ppul23547-bib-0016){ref-type="ref"} the inspiratory flow ratio is increased and consequently the IFR is reduced in patients with DMD compared to healthy subjects (i.e., a lower IFR value indicates more severe functional impairment). As a sensitivity analysis, IFR values were also calculated using both V\'I,max(t) and V\'I,max(FVC) from the same individual maneuver, and the highest (i.e., best) IFR expressed as percentage was selected for comparison. The reserve in flow was also analyzed as IFR and expressed in L/sec, determined as the difference V\'I,max(FVC) -- V\'I,max(t).

![Assessment of inspiratory function. Inspiratory flow‐volume curve. The subject breathes tidally until a repeatable inspiratory tidal flow--volume curve is obtained; he then expires to residual volume and makes a maximum inspiratory effort to total lung capacity. The largest value during tidal breathing (V\'I,max(t)) and the largest value of inspiratory flow during the maximum effort maneuver (V\'I,max(FVC)) are determined. The inspiratory flow ratio is calculated as V\'I,max(t)/V\'I,max(FVC) and the IFR is calculated as 1 − (V\'I,max(t)/V\'I,max(FVC)) and expressed as percentage. In addition, the difference V\'I,max(FVC) − V\'I,max(t) is expressed as IFR in L/sec.](PPUL-52-508-g001){#ppul23547-fig-0001}

Change from baseline and differences in treatment groups was analyzed using a mixed model for repeated measures (MMRM) using SAS 9.3,[24](#ppul23547-bib-0024){ref-type="ref"} as described previously.[17](#ppul23547-bib-0017){ref-type="ref"} For comparisons between treatment groups, all available data from all post‐baseline visits were used as response variables in the model. Treatment group, visit, and the interaction between the treatment group and visit were used as fixed factors in the model and the baseline assessment as a covariate. Within‐subject coefficients of variation and correlations between parameters (Spearman\'s rho) were calculated using R.[25](#ppul23547-bib-0025){ref-type="ref"}

RESULTS {#ppul23547-sec-0004}
=======

Patient demographics of the DELOS trial have been previously reported[17](#ppul23547-bib-0017){ref-type="ref"} and are briefly summarized in Table [1](#ppul23547-tbl-0001){ref-type="table-wrap"}. At baseline, patients (N = 64) had an average age of 14.3 years (SD: 2.7, range: 10.1--19.0), 59 (92.2%) were non‐ambulatory and 28 (43.8%) had never used GC. Previous GC users had stopped taking GCs at least 12 months prior to enrollment (mean: 3.7 years, SD: 2.1 years, range: 0.9--8.9 years).[17](#ppul23547-bib-0017){ref-type="ref"} The baseline characteristics of pulmonary function parameters are shown in Table [2](#ppul23547-tbl-0002){ref-type="table-wrap"}; there were no statistically significant differences between treatment groups for any of the expiratory and inspiratory function tests and for maximum static airway pressures.

###### 

Patient Characteristics of the DELOS Trial Population

                             Idebenone (N = 31)   Placebo (N = 33)   Total (N = 64)
  -------------------------- -------------------- ------------------ ----------------
  Age (years)                13.5 (2.7)           15.0 (2.5)         14.3 (2.7)
  Non‐ambulatory (%)         28 (90.3)            31 (93.9)          59 (92.2)
  Prior glucocorticoid use                                           
  Yes (%)                    17 (54.8)            19 (57.6)          36 (56.3)
  No (%)                     14 (45.2)            14 (42.4)          28 (43.8)
  PEF %p strata                                                      
  PEF \<40%                  5 (16.1)             7 (21.2)           12 (18.8)
  PEF 40--80%                26 (83.9)            26 (78.8)          52 (81.3)

© 2016 Wiley Periodicals, Inc.

###### 

Baseline Pulmonary Function of the DELOS Trial Population

                                   Idebenone (N = 31)   Placebo (N = 33)   Between‐group comparison *P*‐value[\*](#ppul23547-note-0002){ref-type="fn"}   Total (N = 64)
  -------------------------------- -------------------- ------------------ ----------------------------------------------------------------------------- ----------------
  Expiratory function                                                                                                                                    
  PEF (L/min)                      217.7 (48.6)         233.8 (59.6)       0.241                                                                         226.0 (54.7)
  PEF%p                            53.5 (10.3)          54.2 (13.2)        0.811                                                                         53.8 (11.8)
  FVC (L)                          1.88 (0.47)          1.86 (0.50)        0.879                                                                         1.87 (0.48)
  FVC%p                            55.3 (15.8)          50.4 (20.0)        0.277                                                                         52.8 (18.1)
  FEV1 (L)                         1.57 (0.38)          1.60 (0.54)        0.805                                                                         1.58 (0.47)
  FEV1%p                           53.6 (16.1)          49.5 (20.6)        0.375                                                                         51.4 (18.5)
  Inspiratory function                                                                                                                                   
  V\'I, max(t) (L/sec)             0.73 (0.22)          0.80 (0.46)        0.456                                                                         0.76 (0.36)
  V\'I, max(FVC) (L/sec)           2.77 (0.88)          2.82 (0.87)        0.838                                                                         2.79 (0.87)
  Inspiratory flow ratio           28.7 (12.3)          29.8 (15.0)        0.750                                                                         29.3 (13.7)
  IFR (%)                          71.3 (12.3)          70.2 (15.0)        0.750                                                                         70.8 (13.7)
  IFR (L/sec)                      2.04 (0.89)          2.01 (0.91)        0.921                                                                         2.03 (0.89)
  Maximum static airway pressure                                                                                                                         
  MIP (cmH~2~O)                    47.3 (24.4)          44.6 (16.9)        0.609                                                                         45.9 (20.8)
  MIP%p                            43.5 (22.2)          38.5 (16.9)        0.318                                                                         41.0 (19.6)
  MEP (cmH~2~O)                    40.6 (15.6)          39.7 (16.6)        0.827                                                                         40.1 (16.0)
  MEP%p                            28.3 (12.2)          25.1 (12.2)        0.307                                                                         26.6 (12.2)

Data are mean (SD) or number (%). IFR, inspiratory flow reserve.

By *t*‐test.

© 2016 Wiley Periodicals, Inc.

As previously described in the original report of this study,[17](#ppul23547-bib-0017){ref-type="ref"} treatment effects for idebenone were observed for the change in PEF, FEV1, and FVC (reported as percent predicted or non‐normalized values). Specifically, between‐group differences for PEF%p, PEF, FVC, FEV1%p, and FEV1 for the change from baseline to week 52 were statistically significant and between‐group differences for FVC%p reached a strong trend (*P *\< 0.05 at weeks 13, 26, and 39; *P* = 0.082 at week 52).[17](#ppul23547-bib-0017){ref-type="ref"} Overall, the results of the study indicate a consistent slowing of the decline of these pulmonary function outcomes. On the other hand, no statistically significant differences between idebenone and placebo groups were seen for changes in MIP and MEP. The lack of effect for the outcome in MIP and MEP could be explained by severe disability at baseline (Table [2](#ppul23547-tbl-0002){ref-type="table-wrap"}) and early appearance of floor effects. Historically, decline in MIP and MEP have been shown to be among the first signs of respiratory dysfunction in DMD.[15](#ppul23547-bib-0015){ref-type="ref"} Baseline data from this study are consistent with data reported from a large natural history study demonstrating severely reduced values of MIP and MEP at very young ages.[26](#ppul23547-bib-0026){ref-type="ref"}, [27](#ppul23547-bib-0027){ref-type="ref"}, [28](#ppul23547-bib-0028){ref-type="ref"} Furthermore, in patients 10--18 years of age as included in the DELOS study, MIP and MEP do not consistently decline[28](#ppul23547-bib-0028){ref-type="ref"} which could have influenced the outcomes for these parameters.

Characterization of V\'I,max(FVC) in DMD Patients {#ppul23547-sec-0005}
-------------------------------------------------

Patients enrolled in the DELOS trial had abnormal V\'I,max(FVC) at baseline (2.79 L/sec, SD: 0.87; Table [2](#ppul23547-tbl-0002){ref-type="table-wrap"}) consistent with the data reported by De Bruin et al.[16](#ppul23547-bib-0016){ref-type="ref"} V\'I,max(FVC) correlated well with PEF (r = 0.63), FEV1 (r = 0.51), and FVC (r = 0.47) (Table [3](#ppul23547-tbl-0003){ref-type="table-wrap"}), and was reliably performed by all patients. On the other hand, V\'I,max(FVC) correlated weakly with MEP (r = 0.26).

###### 

Correlation of Inspiratory and Expiratory Respiratory Function Parameters and Static Mouth Pressures

  Spearman\'s rho (r)      V\'I,max(FVC) (L/sec)   IFR (%)   IFR (L/sec)
  ------------------------ ----------------------- --------- -------------
  Inspiratory flow ratio   −0.45                   −1.00     −0.77
  IFR (%)                  0.45                    ---       0.77
  IFR (L/sec)              0.89                    0.77      ---
  V\'I,max(FVC) (L/sec)    ---                     0.45      0.89
  V\'I, max (t) (L/sec)    0.11                    −0.79     −0.28
  PEF (L/min)              0.63                    0.37      0.60
  FVC (L)                  0.47                    0.08      0.35
  FEV1 (L)                 0.51                    0.19      0.42
  MEP (cm H~2~O)           0.26                    0.01      0.18
  MIP (cm H~2~O)           −0.40                   −0.18     −0.36

© 2016 Wiley Periodicals, Inc.

Additional analysis revealed that V\'I,max(FVC) was similar irrespective of GC use and ambulatory status at baseline (Table [4](#ppul23547-tbl-0004){ref-type="table-wrap"}). On the other hand, as expected, older patients (above 14 years, median age of the study) had larger V\'I,max(FVC) compared to the younger patient subgroup (below 14 years), probably due to body growth. As the V\'I,max(t) did not differ between age groups, this resulted in higher (e.g., better preserved) IFR in older patients compared to younger patients.

###### 

Baseline Inspiratory Function Stratified by GC Use, Median Age, and Ambulatory Status

                                 Patients (n)   V\'I,max(FVC) (L/sec)   V\'I,max(t) (L/sec)   IFR (%)       IFR (L/sec)
  ------------------------------ -------------- ----------------------- --------------------- ------------- -------------
  All patients                   64             2.79 (0.87)             0.76 (0.36)           70.7 (13.7)   2.03 (0.89)
  GC‐naïve patients              28             2.83 (0.93)             0.66 (0.30)           74.9 (12.0)   2.17 (0.92)
  Previous GC users              36             2.76 (0.82)             0.85 (0.39)           67.5 (14.2)   1.92 (0.87)
  Age ≥14 years                  32             3.07 (0.94)             0.73 (0.37)           74.6 (12.4)   2.34 (0.97)
  Age \<14 years                 32             2.52 (0.70)             0.80 (0.36)           66.9 (14.0)   1.72 (0.68)
  Non‐ambulatory patients only   59             2.82 (0.84)             0.76 (0.36)           71.1 (13.7)   2.06 (0.89)

Data are mean (SD).

© 2016 Wiley Periodicals, Inc.

Longitudinal Change in V\'I,max(FVC) and IFR and Effect of Idebenone {#ppul23547-sec-0006}
--------------------------------------------------------------------

During the study period, V\'I,max(FVC) continued to decline in patients on placebo, with a change from baseline to week 52 of −0.29 L/sec (95%CI: −0.51, −0.08; *P* = 0.008). Conversely, among patients in the idebenone group, the V\'I,max(FVC) remained stable throughout the study period with a change from baseline to week 52 of 0.01 L/sec (95%CI: −0.22, 0.24; *P* = 0.950), resulting in a between‐group difference of 0.30 L/sec (95%CI: −0.01, 0.62; *P* = 0.061) (Fig. [2](#ppul23547-fig-0002){ref-type="fig"}).

![Change of V\'I,max(FVC) from baseline to week 52. Data are estimated means, standard errors (graph), and 95%CI from the mixed model for repeated measures for change from baseline to week 13, 26, 39, and 52.](PPUL-52-508-g002){#ppul23547-fig-0002}

Likewise, during the study period, IFR increased by 2.8% (indicating improvement; 95%CI: −1.3, 6.8; *P* = 0.174) among patients receiving idebenone and decreased by −3.0% (indicating worsening; 95%CI: −6.8, 0.7; *P* = 0.114) among patients on placebo with a significant between‐group difference at 52 weeks of 5.78% (95%CI: 0.28, 11.27; *P* = 0.040) (Fig. [3](#ppul23547-fig-0003){ref-type="fig"}).

![Change of IFR (in %) from baseline to week 52. Data are estimated means, standard errors (graph), and 95%CI from the mixed model for repeated measures for change from baseline to week 13, 26, 39, and 52.](PPUL-52-508-g003){#ppul23547-fig-0003}

Similar results were obtained when the best IFR was calculated from V\'I,max(t) paired with V\'I,max(FVC), both obtained from one individual maneuver. For this sensitivity analysis, the change from baseline to week 52 was 3.3% (95%CI: −1.2, 7.8; *P* = 0.149) for the idebenone group compared to −1.7% (95%CI: −5.9, 2.5; *P* = 0.430) for the placebo group. The between‐group difference for the change from baseline to week 52 was 5.0% (95%CI: −1.2, 11.2; *P* = 0.113) in favor of idebenone treatment.

In an alternative analysis, IFR was calculated as the difference between V\'I,max(FVC) and V\'I,max(t) and expressed in L/sec. Here, the idebenone‐treated patients also remained stable compared to a steady decline, indicating worsening, seen in patients in the placebo group (Fig. [4](#ppul23547-fig-0004){ref-type="fig"}). The between‐group difference was statistically significant from week 26 onwards and reached a difference of 0.35 L/sec at week 52 (95%CI: 0.07, 0.63; *P* = 0.016).

![Change of IFR (in L/sec) from baseline to week 52. Data are estimated means, standard errors (graph), and 95%CI from the mixed model for repeated measures for change from baseline to week 13, 26, 39, and 52.](PPUL-52-508-g004){#ppul23547-fig-0004}

DISCUSSION {#ppul23547-sec-0007}
==========

This additional analysis of the DELOS trial indicates that inspiratory function is significantly impaired in 10--18‐year‐old DMD patients not taking GC and demonstrates that idebenone significantly reduces the loss of pulmonary function as assessed by inspiratory flow reserve. A non‐significant trend (*P* = 0.061) favoring idebenone at week 52 was also observed on V\'I,max(FVC). These findings corroborate previously reported data on the efficacy of idebenone in preserving expiratory muscle function in this patient population.[17](#ppul23547-bib-0017){ref-type="ref"}

Maximum inspiratory flow (e.g., the largest inspiratory flow generated during an inspiratory FVC maneuver, V\'I,max (FVC)) provides an estimate of inspiratory muscle function in patients with DMD.[16](#ppul23547-bib-0016){ref-type="ref"} In chronic neuromuscular diseases, decreases in V\'I,max(FVC) may be proportionately greater than maximum expiratory flow.[29](#ppul23547-bib-0029){ref-type="ref"}, [30](#ppul23547-bib-0030){ref-type="ref"} This difference, which in DMD is augmented by the involvement of the diaphragm, is due to the effort--dependence of V\'I,max(FVC) and is amplified by an increase in lung recoil that offsets the effects of muscle weakness on expiration, but decreases the flow produced by a given (negative) pleural pressure on inspiration.[31](#ppul23547-bib-0031){ref-type="ref"}

De Bruin et al.[16](#ppul23547-bib-0016){ref-type="ref"} have shown that maximum inspiratory flow is reduced in patients with DMD, and as a result of that the inspiratory flow ratio is increased and consequently the IFR reduced, both indicative of inspiratory function loss. The analysis we performed on the DELOS population generally confirms these findings. However, DMD patients in DELOS had higher V\'I,max(FVC) at baseline (2.77 L/sec in the idebenone group and 2.82 L/sec in the placebo group) than those in the De Bruin study (2.17 L/sec).[16](#ppul23547-bib-0016){ref-type="ref"} Similarly, FVC was also higher in DELOS (1.88 L in the idebenone group and 1.86 L in the placebo group) than in the De Bruin study (1.64 L). Both differences could be explained by the older age (13.5 years and 15.0 years in the idebenone and placebo groups, respectively vs. 12.8 years) and the fact that patients were taller (157 cm and 162 cm in the idebenone and placebo groups, respectively vs. 148 cm)[16](#ppul23547-bib-0016){ref-type="ref"} in DELOS. In addition, since the De Bruin study was published over 10 years ago, improved standards of care may also have accounted for a better preserved pulmonary function in patients with DMD enrolled in DELOS. Interestingly, both V\'I,max(FVC) and IFR were not better in previous GC users compared to GC‐naïve patients, suggesting that the favorable long‐term effect of GC use on pulmonary function had disappeared by the time patients enrolled in the study.

Our findings for V\'I,max(FVC) and IFR point toward a protective role of idebenone on inspiratory muscle function such as the diaphragm, which is of clinical relevance. Indeed, contrary to earlier suggestions that the diaphragm might be selectively spared until a late phase of the disease,[32](#ppul23547-bib-0032){ref-type="ref"} it has been demonstrated that diaphragm thickness is increased in patients with DMD below the age of 12 years due to connective tissue infiltration and fat deposition.[33](#ppul23547-bib-0033){ref-type="ref"} Diaphragm pseudo‐hypertrophy, which is similar to that observed in some limb muscle groups, is associated with significant reductions in spirometric measurements such as FEV~1~, FVC, and PEF.[33](#ppul23547-bib-0033){ref-type="ref"} Moreover, the diaphragm is in constant use and often displays the most severe pathology, as demonstrated in animal models of muscular dystrophy, leading to the conclusion that exercise may exacerbate degeneration.[34](#ppul23547-bib-0034){ref-type="ref"}

The clinical interpretation of the results reported here is limited by the fact that dynamic inspiratory function tests are currently not performed in the routine follow‐up of DMD patients. Furthermore, as this is the second report on inspiratory function in DMD patients following the first description by De Bruin et al.,[16](#ppul23547-bib-0016){ref-type="ref"} there is currently a lack of reference data from natural history studies that would enable interpretation of the clinical relevance of the observed outcomes. Clearly, further work is needed to correlate changes in inspiratory functions tests to pulmonary function test outcomes commonly accepted to be of clinical relevance to DMD patients, such as decline in FVC or PEF. As available data are currently not sufficient to allow for such comparisons, measures of inspiratory function and changes observed are to be regarded as exploratory in nature and therefore robust clinical conclusions cannot be derived at this time. However, as inspiratory maneuvers assess the function of different muscle groups compared to those assessed during expiratory function tests (e.g., FVC, PEF), such data could still provide useful information.

In summary, idebenone reduced the loss of inspiratory pulmonary function as assessed by V\'I,max(FVC) and IFR in patients with DMD. Stabilization of respiratory muscle function may potentially delay the emergence of respiratory failure in these patients. Although the clinical interpretation of these data is currently limited, these findings nevertheless expand on the previously reported effect of idebenone on expiratory muscle function in DMD patients and are of special interest as inspiratory and expiratory maneuvers rely on a different set of muscles. Studies of longer duration will be needed to further corroborate the encouraging treatment effects of idebenone on respiratory function outcomes as observed in the randomized controlled DELOS study. Of particular relevance will be the correlation between changes in pulmonary function outcomes and the clinical course over time. In this context, it is of particular interest that patients in the idebenone group of the DELOS study experienced fewer and shorter bronchopulmonary complications (such as airway infections) compared to patients in the placebo group, which is of clinical relevance.[35](#ppul23547-bib-0035){ref-type="ref"}
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